Bausch & Lomb signs agreement
Bausch & Lomb has entered into a collaborative research agreement with Galapagos NV, a drug discovery company based in Mechelen, Belgium, giving B&L the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.
Rochester, NY-Bausch & Lomb (B&L) has entered into a collaborative research agreement with Galapagos NV, a drug discovery company based in Mechelen, Belgium, giving B&L the exclusive option to license select Galapagos compounds as development candidates for therapeutic uses in ophthalmic diseases.
"The small-molecule compounds under evaluation have very attractive in vitro and in vivo profiles," said Praveen Tyle, PhD, B&L chief scientific officer. "Our intent is to develop these compounds as unique therapies, tapping our research expertise in ophthalmic diseases."
Onno van de Stolpe, chief executive officer of Galapagos, said, "Our collaboration with B&L gives us the opportunity to leverage select compounds in a therapeutic area that we would not otherwise pursue."
